Addressing non-adherence to antipsychotic medication: A harm-reduction approach

Journal of Psychiatric and Mental Health Nursing

Volumn 19, Issue 1, 2012, Pages 85-96

  Aldridge, M A ^a  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Evidence based practice; Medication management

Indexed keywords

BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; OLANZAPINE;

ADOLESCENT; ARTICLE; CASE REPORT; HARM REDUCTION; HUMAN; MALE; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; SCHIZOPHRENIA;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; HARM REDUCTION; HUMANS; MALE; PATIENT COMPLIANCE; SCHIZOPHRENIA;

EID: 84855289245     PISSN: 13510126     EISSN: 13652850     Source Type: Journal    
DOI: 10.1111/j.1365-2850.2011.01809.x     Document Type: Article

References (105)

1. Amador X.F. & David A. (2005) Insight and Psychosis: Awareness of Illness in Schizophrenia and Related Disorders. Oxford University Press, Oxford.
2. American Psychiatric Association (2004) Practice Guideline for the Treatment of Patients with Schizophrenia, 2nd edn. American Psychiatric Association, Arlington, VA.
3. Barnes T.R.E. & Curson D.A. (1994) Long-acting depot antipsychotics: a risk-benefit assessment. Drug Safety 10, 464-479.
4. Barnes T.R.E., Leeson V.C., Mutsatsa S.H., etal. (2008) Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia. The British Journal of Psychiatry 193, 203-209.
5. Bindman J., Maingay S. & Szmukler G. (2003) The human rights act and mental health legislation. The British Journal of Psychiatry 182, 91-94.
6. Bola J.R. (2006) Medication-free research in early episode schizophrenia: evidence of long-term harm? Schizophrenia Bulletin 32, 288-296.
7. Bradstreet S. & Norris R. (2004) All You Need to Know? Scottish Survey of People's Experience of Psychiatric Drugs. Scottish Association for Mental Health. Available at: (accessed 20 September 2009).
8. British Medical Association (2010) British National Formulary (60). BMJ Publishing Group Ltd., RPS Publishing, London.
9. Buckley P.F., Foster A., Patel N.C., etal. (2009) Adherence to Mental Health Treatment. Oxford University Press, Oxford, NY.
10. Burns T. & Dawson J. (2009) Community treatment orders: how ethical without experimental evidence? Psychological Medicine 39, 1583-1586.
11. Cairns R., Maddock C., Buchanan A., etal. (2005) Prevalence and predictors of mental incapacity in psychiatric in-patients. The British Journal of Psychiatry 187, 379-385.
12. Care Services Improvement Partnership (CSIP), Royal College of Psychiatrists (RCPsych), Social Care Institute for Excellence (SCIE) (2007) A common purpose: recovery in future mental health services (Joint Position Paper) Social Care Institute for Excellence.
13. Castle D, Morgan V, Jablensky A. (2002) Antipsychotic use in Australia: the patients' perspective. Australian and New Zealand Journal of Psychiatry 36, 633-641.
14. Chue P. (2011) Risperidone long-acting injection. In: Antipsychotic Long-Acting Injections (eds Haddad, P., Lambert, T. & Lauriello, J.), pp. 93-130. Oxford University Press, Oxford, NY.
15. Chue P. & Emsley R. (2007) Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics. CNS Drugs 21, 441-448.
16. Clatworthy J., Bowskill R., Parham R., etal. (2009) Understanding medication non-adherence in bipolar disorders using a necessity-concerns framework. Journal of Affective Disorders 116 51-55.
17. Crepaz-Keay D. (1999) Drugs. In: This is Madness: A Critical Look at Psychiatry and the Future of Mental Health Services (eds Newnes, C., Holmes, G. & Dunn, C.), pp. 91-96. PCCS Books, Llangarron.
18. Cuesta M.J., Peralta V. & Zarzuela A. (2000) Reappraising insight in psychosis: multi-scale longitudinal study. The British Journal of Psychiatry 177, 233-240.
19. Dawson J. (2005) Community Treatment Orders: International Comparisons. Otago University Press, Dunedin.
20. Dilsaver S.C. & Alessi N.E. (1988) Antipsychotic withdrawal symptoms: phenemonology and pathophysiology. Acta Psychiatrica Scandinavica 77, 241-246.
21. Duncan E., Best C. & Hagen S. (2010) Shared decision making interventions for people with mental health conditions. Cochrane Database of Systematic Reviews, Issue 1. Art. No. CD 007297.
22. Emsley R., Chiliza B., Asmal L., etal. (2011) Long-acting injectable antipsychotics in early psychosis. In: Antipsychotic Long-Acting Injections (eds Haddad, P., Lambert, T. & Lauriello, J.), pp. 145-162. Oxford University Press, Oxford, NY.
23. Falloon I.R.H. (2006) Antipsychotic drugs: when and how to withdraw them? Psychotherapy and Psychosomatics 75, 133-138.
24. Fenton W.S., Blyer C.R. & Heinssen R.K. (1997) Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophrinia Bulletin 23, 637-651.
25. Foster K., Meltzer H., Gill B., etal. (1996) Adults with a Psychotic Disorder Living in the Community. OPCS Surveys of Psychiatric Morbidity in Great Britain, Report 8. HMSO, London.
26. Gabel W. & Piezcker A. (1985) One-year outcome of schizophrenic patients: the interaction of chronic and neuroleptic treatment. Psychopharmacology 18, 235-239.
27. Glazer W.M. & Kane J.M. (1992) Depot neuroleptic therapy: an underutilized treatment option. Journal of Clinical Psychiatry 53, 426-433.
28. Gray R., Wykes T. & Gournay K. (2002) From compliance to concordance: a review of the literature on interventions to enhance compliance with antipsychotic medication. Journal of Psychiatric and Mental Health Nursing 9, 277-284.
29. Haddad P. & Fleischhacker W.W. (2011) Adverse effects and antipsychotic long-acting injections. In: Antipsychotic Long-Acting Injections (eds Haddad, P., Lambert, T. & Lauriello, J.), pp. 47-69. Open University Press, Oxford, NY.
30. Hall W. (2007) Harm Reduction Guide to Coming Off Psychiatric Drugs. The Icarus Project and Freedom Center, San Francisco, CA.
31. Hamilton B. & Roper C. (2006) Troubling 'insight': power and possibilities in mental health care. Journal of Psychiatric and Mental Health Nursing 13, 416-422.
32. Harrow M. & Jobe T.H. (2007) Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: a 15-year multifollow-up study. The Journal of Nervous and Mental Disease 195, 406-414.
33. Hawton K., Sutton L., Haw C., etal. (2005) Schizophrenia and suicide: systematic review of risk factors. The British Journal of Psychiatry 187, 9-20.
34. Helgason L. (1990) Twenty-year follow-up of first psychiatric presentation for schizophrenia: what could have been prevented? Acta Psychiatrica Scandinavica 81, 231-235.
35. Hill S. & Laugharne R. (2006) Decision making and information seeking preferences among psychiatric patients. Journal of Mental Health 15, 75-84.
36. Ho B.C., Alicata D., Ward J., etal. (2003) Untreated initial psychosis: relation to cognitive deficits and brain morphology in first-episode schizophrenia. American Journal of Psychiatry 160, 142-148.
37. Hogan T.P., Awad A.G. & Eastwood R. (1983) A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychological Medicine 13, 177-183.
38. Holmes G. & Hudson M. (2003) Coming off medication. Open Mind 123, 14-15.
39. Hope T. (2002) Evidence-based patient choice and psychiatry. Evidence Based Mental Health 5, 100-101.
40. Horne R. & Weinman J. (1995) The Beliefs about Medication Questionnaire: A New Measure for Assessing Lay Beliefs about Medicines. BPS, London.
41. Hosalli P. & Davis J.M. (2009) Depot risperidone for schizophrenia (Review). The Cochrane Library Issue 1.
42. Irwin D.S., Weitzel W.D. & Morgan D.W. (1971) Phenothiazine intake and staff attitudes. American Journal of Psychiatry 127, 1631-1635.
43. Jeste D.V., Depp C.A. & Palmer B.W. (2006) Magnitude of impairment in decisional capacity in people with schizophrenia compared to normal subjects: an overview. Schizophrenia Bulletin 32, 121-128.
44. Kinderman P. & Cooke A., eds (2000) Recent advances in understanding mental illness and psychotic experiences: a report by the British Psychological Society Division of Clinical Psychology. The British Psychological Society.
45. Kisely S.R., Campbell L.A. & Preston N.J. (2010) Compulsory community and involuntary outpatient treatment for people with severe mental disorders (Review). The Cochrane Library Issue 3.
46. Lacro J.P., Dunn L.B., Dolder C.R., etal. (2002) Prevalence of and risk factors for medication non-adherence in patients with schizophrenia: a comprehensive review of recent literature. Journal of Clinical Psychiatry 63, 892-909.
47. Lauriello J. & Beck N. (2011) Recently approved long-acting antipsychotic injections: paliperidone LAI and olanzapine LAI. In: Antipsychotic Long-Acting Injections (eds Haddad, P., Lambert, T. & Lauriello, J.), pp. 131-144. Oxford University Press, Oxford, NY.
48. Lecompte D. & Pelc I. (1996) A cognitive-behavioral program to improve compliance with medication in patients with schizophrenia. International Journal of Mental Health 25, 51-56.
49. Lenton S. & Single E. (1998) The definition of harm reduction. Drug & Alcohol Review 17, 213-220.
50. Lincoln T.M., Wilhelm K. & Nestoriuc Y. (2007) Effectiveness of psychoeducation for relapse, symptoms, knowledge, adherence and functioning in psychotic disorders: a meta-analysis. Schizophrenia Research 96, 2232-2245.
51. Marshall M., Lewis S., Lockwood A., etal. (2005) Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Archive of General Psychiatry 62, 975-983.
52. McCabe R. & Priebe S. (2004) Explanatory models of illness in schizophrenia: comparison of four ethnic groups. The British Journal of Psychiatry 185, 25-30.
53. McEvoy J.P. (2004) The Relationship between insight into psychosis and compliance with medications. In: Insight and Psychosis: Awareness of Illness in Schizophrenia and Related Disorders (eds Amador, X. & David, A.), pp. 311-333., 2nd edn. Oxford University Press, Oxford, NY.
54. McIntosh A., Conlon L., Lawrie S., etal. (2006) Compliance therapy for schizophrenia. Cochrane Database of Systematic Reviews, Issue 4. Art. No. CD 003442.
55. Merinder L.B. (2000) Education in schizophrenia: a review. Acta Psychiatrica Scandinavica 102, 98-106.
56. Miller B.J. (2008) Antipsychotic discontinuation in first-episode psychosis. Journal of Psychiatric Practice 14, 289-300.
57. Molodynski A., Rugkasa J. & Burns T. (2010) Coercion and compulsion in community mental health care. British Medical Bulletin 95, 105-119.
58. Moncrieff J. (2006) Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatrica Scandinavica 114, 1-11.
59. Moncrieff J. (2008) The Myth of Chemical Cure: A Critique of Psychiatric Drug Treatment. Palgrave Macmillan, Basingstoke.
60. Morken G., Widen J.H. & Grawe R.W. (2008) Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry 8, 123-129.
61. Munetz M., Galon P.A. & Frese F.J. III (2003) The ethics of mandatory community treatment. The Journal of the American Academy of Psychiatry and the Law 31, 173-183.
62. National Institute for Health and Clinical Excellence (2002) Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Available at: (accessed 1 March 2008).
63. National Institute for Health and Clinical Excellence (2009) Schizophrenia: core interventions. In: The Treatment and Management of Schizophrenia in Primary and Secondary Care (Update): National Clinical Practice Guideline Number 82.
64. National Institute for Health and Clinical Excellence (2010) Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (update). The British Psychological Society and The Royal College of Psychiatrists.
65. NMC (2008) The Code: Standards of Conduct, Performance and Ethics for Nurses and Midwives. Nursing and Midwifery Council, London.
66. Nose M., Barbui C., Gray R., etal. (2003) Clinical interventions for treatment nonadherence in psychosis: meta-analysis. The British Journal of Psychiatry 183, 197-206.
67. Olofinjana B. & Taylor D. (2005) Antipsychotic drugs - information and choice: a patient survey. Psychiatric Bulletin 29, 369-371.
68. Overall J.E. & Gorham D.R. (1962) The Brief Psychiatric Rating Scale (BPRS). Psychological Reports 10, 799-812.
69. Owen G.S., Szmukler G., Richardson G., etal. (2009) Mental capacity and psychiatric in-patients: implications for the new mental health law in England and Wales. The British Journal of Psychiatry 195, 257-263.
70. Patel M.X., Nikolaou V. & David A.S. (2003) Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychological Medicine 33, 83-89.
71. Patel M.X., De Zoysa N., Baker D., etal. (2005) Antipsychotic depot medication and attitudes of community psychiatric nurses. Journal of Psychiatric and Mental Health Nursing 12, 237-244.
72. Patel M.X., De Zoysa N., Bernadt M., etal. (2008a) A cross-sectional study of patients' perspectives on adherence to antipsychotic medication: depot versus oral. Journal of Clinical Psychiatry 69, 1548-1556.
73. Patel M.X., Yeung F.K.K., Haddad P.M., etal. (2008b) Psychiatric nurses' attitudes to antipsychotic depots in Hong Kong and comparison with London. Journal of Psychiatric and Mental Health Nursing 15, 758-766.
74. Patel M.X., De Zoysa N., Bernadt M., etal. (2009) Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. Journal of Psychopharmacology 23, 789-796.
75. Patel M.X., de Zoysa N., Bernadt M., etal. (2010) Are depot antipsychotics more coercive than tablets? The patient's perspective. Journal of Psychopharmacology 24, 1483-1489.
76. Pereira S. & Pinto R. (1997) A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiatrica Scandinavica 95, 464-468.
77. Peters E.R., Joseph S.A. & Garety P.A. (1999) Measurement of delusional ideation in the normal population: introducing the PDI (Peters etal. Delusions Inventory). Schizophrenia Bulletin 25, 553-576.
78. Prime Minister's Commission on the Future of Nursing and Midwifery in England (2010) Front Line Care: the future of nursing and midwifery in England. Report of the Prime Minister's Commission on the Future of Nursing and Midwifery in England. 2010 Crown Copyright.
79. Puschner B., Angermeyer M.C., Leese M., etal. (2009) Course of adherence to medication and quality of life in people with schizophrenia. Psychiatry Research 165, 224-233.
80. Rainer M.K. (2008) Risperidone long-acting injection: a review of its long term safety and efficacy. Neuropsychiatric Disease and Treatment 4, 919-927.
81. Rattehalli R.D., Jayaram M.B. & Smith M. (2010) Risperidone versus placebo for schizophrenia. Cochrane Database of Systematic Reviews, Issue 1. Art. No. CD 006918.
82. Read J. (2005) Coping with Coming Off: Mind's Research into the Experiences of People Trying to Come Off Psychiatric Drugs. MIND Publications, London.
83. Read J., Haslam N., Sayce L., etal. (2006) Prejudice and schizophrenia: a review of the 'mental illness is an illness like any other' approach. Acta Psychiatrica Scandinavica 114, 303-318.
84. Rethink (2010) Mental Health Services 'breaching human rights', says Rethink. Press Release 27 October 2010. Available at: (accessed 1 March 2011).
85. Sackett D.L. & Haynes B.R. (1976) Compliance with Therapeutic Regimens. Johns Hopkins University Press, Baltimore, MD.
86. Schooler N.R. (2003) Relapse and rehospitalisation: comparing oral and depot antipsychotics. Journal of Clinical Psychiatry 64, 14-17.
87. Soskis D.A. (1978) Schizophrenic and medical inpatients as informed drug consumers. Archives of General Psychiatry 35, 645-649.
88. Stant A.D., TenVergert E.M., Wunderink L., etal. (2007) Economic consequences of alternative medication strategies in first episode non-affective psychosis. European Psychiatry 22, 347-353.
89. Staring A.B.P., Van der Gaag M., Koopmans G.T., etal. (2010) Treatment adherence therapy in people with psychotic disorders: randomised controlled trial. The British Journal of Psychiatry 197, 448-455.
90. Szmukler G. & Holloway F. (1998) Mental health legislation is now a harmful anachronism. Psychiatric Bulletin 22, 662-665.
91. Tacchi M.J. & Scott J. (2005) Improving Adherence in Schizophrenia and Bipolar Disorders. John Wiley & Sons, Ltd., Hoboken, NJ.
92. Tacchi M.J., Nendick J. & Scott J. (2011) Patient choice and improving the uptake of longacting injectable medication. In: Antipsychotic Long-Acting Injections (eds Haddad, P., Lambert, T. & Lauriello, J.), pp. 185-208. Open University Press, Oxford, NY.
93. Taylor D., Paton C. & Kapur S. (2009) The South London and Maudsley NHS Foundation Trust Oxleas NHS Foundation Trust Prescribing Guidelines, 10th edn. Informa healthcare, London.
94. The British Psychological Society (2000) Recent Advances in Understanding Mental Illness and Psychotic Experience. The British Psychological Society, Leicester.
95. Thomas A., Katsabouris G. & Bouras N. (1997) Staff perception on reduction of medication in patients with chronic schizophrenia. Psychiatric Bulletin 21, 692-694.
96. Ucok A., Polat A., Cakir S., etal. (2006) One year outcome in first episode schizophrenia; predictors of relapse. European Archives of Psychiatry and Clinical Neuroscience 256, 37-43.
97. UK Harm Reduction Alliance (2011) UK Harm Reduction Alliance Definition of Harm Reduction. Available at: (accessed 20 March 2011).
98. Viguera A.C., Baldessarini R.J., Hegarty J.D., etal. (1997) Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Archive of General Psychiatry 54, 49-55.
99. Waddell L. & Taylor M. (2009) Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. The British Journal of Psychiatry 195, 43-50.
100. Warner R. (2004) Recovery from Schizophrenia: Psychiatry and Political Economy, 3rd edn. Brunner-Routledge, Hove and New York.
101. Warner R. (2010) Does the scientific evidence support the recovery model? The Psychiatrist 34, 3-5.
102. Whitaker R. (2004) The case against antipsychotic drugs: a 50-year record of doing more harm than good. Medical Hypotheses 62, 5-13.
103. Williams C.C. & Collin A.A. (2002) The social construction of disability in schizophrenia. Qualitative Health Research 12, 297-309.
104. Wunderink L., Nienhuis F.J., Sytema S., etal. (2007) Guided discontinuation versus maintenance treatment in remitted first episode psychosis: relapse rates and functional outcome. Journal of Clinical Psychiatry 68, 654-661.
105. Zygmunt A., Olfson M., Boyer C.A., etal. (2002) Interventions to improve medication adherence in schizophrenia. American Journal of Psychiatry 159, 1653-1664.